RecruitingMetastatic Castration-resistant Prostate Cancer
XL092 in Patients With Metastatic Castration-Resistant Prostate Cancer
Eligible age
18+ yrs
Accepts
Men
Locations
1 state
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The purpose of this study is to determine how well the study drug XL092 is helping to treat a participant's cancer after 16 weeks of treatment. Researchers will also look at how safe the XL092 is and how well the XL092 is working. XL092 is an oral tablet that will be taken once a day. Participants will return to clinic for regular visits for checkups and tests.
Sponsor: University of Utah
You may qualify if…
- ✓ Participant aged ≥ 18 years
- ✓ Disease criteria:
- ✓ -Histologically or cytologically confirmed prostatic adenocarcinoma without small cell histology
- ✓ Radiographic evidence of metatstatic disease
- ✓ Progression on or after prior treatment with 177Lu-PSMA-617 as determined by clinical investigator
- ✓ ECOG Performance Status ≤ 2.
- ✓ Adequate organ function as defined as:
- ✓ Absolute neutrophil count ≥ 1500/mm3 .
You may not qualify if…
- ✕ Prior treatment with XL092
- ✕ Receipt of any type of small molecule kinase inhibitor, cytotoxic, biologic or other systemic anticancer therapy (including investigational) within 2 weeks or at least 5 half-lives, whichever shorter before first dose of study treatment.
- ✕ Note: Concomitant use of megestrol acetate, androgen-deprivation therapy and bone loss prevention treatment is permitted. Other types of hormonal therapies with similar use require prior approval from the Principal Investigator.
- ✕ Radiation therapy for bone metastasis or any other radiation therapy within 2 weeks before first dose of study treatment. Subjects with clinically relevant ongoing complications from prior radiation therapy are not eligible.
- ✕ Known brain metastases or cranial epidural disease unless adequately treated with radiotherapy and/or surgery (including radiosurgery) and stable for at least 4 weeks before first dose of study treatment.
- ✕ Note: Subjects with an incidental finding of an isolated brain lesion \< 1 cm in diameter may be eligible after Principal Investigator approval if the lesion is radiographically stable for 4 weeks before first dose and does not require treatment per Investigator judgement.
- ✕ Note: Eligible subjects must be neurologically asymptomatic and without corticosteroid treatment at the time of first dose of study treatment.
- ✕ Concomitant anticoagulation with oral anticoagulants except for those specified below:-
Where it's recruiting
Utah
Salt Lake City
Source: ClinicalTrials.gov · NCT06568562 · last updated 2026-06-29